BioCardia (NASDAQ:BCDA) Raised to Sell at Wall Street Zen

BioCardia (NASDAQ:BCDA) was upgraded by analysts at Wall Street Zen to a “sell” rating in a note issued to investors on Saturday.

A number of other research firms also recently commented on BCDA. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioCardia in a research note on Tuesday, June 9th. Zacks Research cut BioCardia from a “hold” rating to a “strong sell” rating in a research note on Monday, July 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of BioCardia in a report on Monday, April 20th. One analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and a consensus target price of $25.00.

BioCardia Price Performance

NASDAQ BCDA opened at $0.83 on Friday. The company has a market capitalization of $9.40 million, a price-to-earnings ratio of -0.91 and a beta of 0.44. BioCardia has a 12 month low of $0.78 and a 12 month high of $2.42. The company’s fifty day moving average price is $0.97 and its two-hundred day moving average price is $1.14.

BioCardia (NASDAQ:BCDA) last released its earnings results on Friday, May 15th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.04). As a group, analysts anticipate that BioCardia will post -0.76 EPS for the current year.

Insider Activity

In other BioCardia news, Director Simon H. Stertzer purchased 70,200 shares of BioCardia stock in a transaction dated Monday, June 22nd. The shares were bought at an average cost of $0.92 per share, for a total transaction of $64,584.00. Following the transaction, the director owned 127,338 shares in the company, valued at $117,150.96. This represents a 122.86% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last 90 days, insiders have bought 146,900 shares of company stock valued at $140,092. Company insiders own 17.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Cetera Investment Advisers acquired a new stake in shares of BioCardia in the second quarter valued at approximately $40,000. DRW Securities LLC acquired a new position in shares of BioCardia during the fourth quarter worth approximately $72,000. Finally, Geode Capital Management LLC boosted its position in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after buying an additional 27,263 shares during the period. Institutional investors own 20.57% of the company’s stock.

BioCardia Company Profile

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.